Table 3.
Correlations between the clinicopathological factors and estrogen receptors (ERa, ERb)
|
Variables |
Expression of ERα |
p value |
Expression of ERβ |
p value |
||
|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | |||
| Age |
55.9 ±13.1 |
52.6±13.1 |
0.12 |
55.8 ±12.3 |
53.6±11.9 |
0.37 |
| Premenopausal |
24 (36.4%) |
42 (63.6%) |
0.24 |
16 (24.2%) |
50 (75.8%) |
0.85 |
| Postmenopausal |
41 (42.7%) |
55 (57.3%) |
|
20 (20.8%) |
76 (79.2%) |
|
| BMI |
22.3 ±2.5 |
21.7 ±2.6 |
0.24 |
21.7 ± 4.5 |
22.0 ± 2.9 |
0.75 |
| Borderline malignancy |
5 (50.0%) |
5 (50.0%) |
0.72 |
6 (60.0%) |
4 (40.0%) |
0.08 |
| FIGO stage I |
10 (25.6%) |
29 (74.4%) |
0.99 |
14 (35.9%) |
25 (64.1%) |
0.06 |
| II |
9 (64.3%) |
5 (35.7%) |
|
2 (14.3 %) |
12 (85.7%) |
|
| III |
34 (44.2%) |
43 (55.8%) |
|
14 (18.2%) |
63 (81.8%) |
|
| IV |
7 (31.8%) |
15 (68.2%) |
|
0 (0%) |
22 (100%) |
|
| Histology |
|
|
|
|
|
|
| Borderline malignancy |
5 (50.0%) |
5 (50.0%) |
0.72 |
6 (60.0%) |
4 (40.0%) |
0.08 |
| Serous adenocarcinoma |
32 (52.5%) |
29 (47.5%) |
0.004 |
11 (18.0%) |
50 (82.0%) |
0.14 |
| Endometrioid adenocarcinoma |
16 (53.3%) |
14 (46.7%) |
|
4 (13.8%) |
26 (86.2%) |
|
| Mucinous adenocarcinoma |
5 (26.3%) |
14 (73.7%) |
|
8 (42.1%) |
11 (57.9%) |
|
| Clear cell adenocarcinoma |
3 (10.3%) |
26 (89.7%) |
|
6 (20.7%) |
23 (79.3%) |
|
| Others |
4 (30.8%) |
9 (69.2%) |
|
1 (7.7%) |
12 (92.3%) |
|
| Recurrence |
|
|
0.14 |
|
|
0.06 |
| ≤ 6M |
8 (42.1%) |
11 (57.9%) |
|
4 (21.1%) |
15 (78.9%) |
|
| > 6M |
31 (48.4%) |
33 (51.6%) |
|
10 (15.6%) |
54 (84.4%) |
|
| No recurrence |
26 (32.9%) |
53 (67.1%) |
|
22 (27.8%) |
57 (72.2%) |
|
| 5-year survival |
|
|
0.47 |
|
|
0.06 |
| Alive |
41 (40.2%) |
61 (59.8%) |
|
26 (25.4%) |
76 (74.6%) |
|
| Dead | 24 (40.0%) | 36 (60.0%) | 10 (16.7%) | 50 (83.3%) | ||